EMERYVILLE, Calif.--(BUSINESS WIRE)--Octant, Inc. (“Octant” or the “Company”), a next-generation, data-driven therapeutics company developing programmable biology and chemistry to build precision ...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Octant, Inc., a synthetic biology drug discovery company designing small molecule, multi-target drug leads for multifactorial diseases announced that it has raised ...
Octant Bio set out on a journey to show that the convergence of synthetic biology, chemistry, and computational techniques could lead to new drugs for patients. That destination is still distant, but ...
“We have been working with Mark for over a year as a Board Member and are thrilled to share that he’s now working with us day-to-day,” said Sri Kosuri, CEO of Octant. “Mark’s unique experience and ...
Data-driven therapeutics company Octant Bio is exploring new frontiers of drug development with $80 million in-pocket and a freshly signed Big Pharma partnership. Octant—a historical instrument used ...
Add Yahoo as a preferred source to see more of our stories on Google. Photo: Andrew Brookes/Getty Images Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results